SURMOUNT-1 · 2022

SURMOUNT-1 — Tirzepatide for weight management

Pivotal trial of tirzepatide for chronic weight management without diabetes.

Headline finding

20.9% body-weight reduction at 72 weeks at 15 mg.

Population
2,539 adults
Duration
72 weeks
Citation
Jastreboff AM et al., NEJM 2022

Summary is editorial; consult the original publication for the full methodology and statistical detail.

Get matched

Want a real recommendation?

Five minutes. Free. No pressure.

Start my consultation